BASKING RIDGE, N.J. - Ipsen (Euronext:IPN; ADR:IPSEY) announced that Cynthia Schwalm has been named President and CEO of Ipsen N.A., responsible for all commercial and medical affairs operations throughout the region. She will assume oversight of all areas supporting the North American Business and will report to Pierre Boulud, EVP of Specialty Care Commercial Operations.
Ms. Schwalm first joined Ipsen in February of this year and has been instrumental in building commercial capabilities and a talented leadership team in preparation for the launch of its first oncology product in the U.S. in 2015, a potential treatment for gastroenteropancreatic neuroendocrine tumors (GEP NETs).
“Cynthia’s wealth of global experience across the pharmaceutical and biopharmaceutical industries uniquely positions her to continue to build upon the growing momentum Ipsen is experiencing in North America and internationally,” said Marc de Garidel, Chairman and CEO, Ipsen. “ We remain committed to strengthening our U.S. presence and positioning the company for the level of success in the U.S. that we have achieved elsewhere.”
Ms. Schwalm is a 30-year industry veteran working in pharmaceuticals, biotechnology and medical devices. She is a member of Harvard JFK School of Public Policy Women’s Leadership Board. Ms. Schwalm earned a B.S. in nursing from the University of Delaware and a M.B.A. from Wharton School of Business at the University of Pennsylvania.
“I am excited to take on the challenge of serving as President and CEO of North America,” Schwalm stated.“We recognize the role of the U.S. in Ipsen’s goal to become a top 10 pharmaceutical company in terms of growth and profitability and are committed to improving the lives of patients.”